US Corporate Board Director Changes SEC Filings — May 14, 2026
The 24 filings reveal a surge in boardroom stability through annual meetings (Fulgent, CSX, Cushman, DMC Global, Delcath, InfuSystem) with director elections mostly passing despite notable opposition in Fulgent (up to 6M withheld for Groves) and CSX (299M against Zillmer). Executive transitions dominate, with orderly retirements and appointments (Selective CIO to interim, RenaissanceRe CFO/CPO to internal successors Jan 2027, AIG independent dir Jun 1, Standex CFO promo), but abrupt separations (CSX EVP immediate, Ocugen CMO May 8, Xponential COO May 13) raise flags. Capital allocation shines with CSX's $5B buyback atop $989M remaining and KeyCorp's $3B program replacing $1B ($280M left) plus $0.205 dividend; equity plans approved widely (Fulgent 2M+1.5M shares, Cushman 12M+, Delcath +1.8M). NeoVolta outlier with Q3 revenue flat YoY at $2M but 9-mo +262% to $13.3M, margins 46% vs 26% YoY despite wider $3M loss. Portfolio trends: Positive sentiments in 7/24 (e.g., insurance, fitness), mixed/neutral elsewhere; no broad insider selling but appointments signal conviction. Implications: Bullish for capital returns in financials/transport, monitor governance dissent and transitions for execution risks.